Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
|Articles|January 6, 2003
As pain management evolves, R.Ph.s can play a greater role
The pain management pharmaceuticals market in the U.S. is being driven by the continued development of selective cyclooxygenase-2 (COX-2) inhibitors, triptans, and extended-release formulations of opioid drugs, according to new analysis by the consulting firm of Frost & Sullivan. In 1997, the company released a similar report. In the intervening six years, the market has undergone dramatic changes.
Advertisement
Advertisement
Related to this article
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
3
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
4
Scripted for Her: The Pharmacist's Role in HPV Prevention
5